SAN DIEGO, July 31, 2012 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the market launch of its proprietary new generation monitoring ...

The San Diego-based pharmaceutical company Prometheus Laboratories has launched PROMETHEUS Anser VDZ, a monitoring test for inflammatory bowel disease patients using vedolizumab. 1. The PROMETHEUS ...

Saliva-based diagnostic detects genes related to the disease and calculates risk. Prometheus has selected DNA Genotek’s Oragene®•DNA product as the sample-collection kit for MyCeliacID™, a ...

Respondr TNF is a proprietary test that uses objective evidence to predict an individual patient's likelihood of response to infliximab, adalimumab or their biosimilars prior to initiation of therapy.

WASHINGTON (AP) -- The Supreme Court unanimously tossed out medical patent claims for Prometheus Laboratories on Tuesday for a test that could help doctors set drug doses for autoimmune diseases like ...

Prometheus Laboratories announced the launch of its monitoring test, PROMETHEUS Anser IFX, which measures infliximab (Remicade; Janssen Biotech) and infliximab antibody levels in one sample to be used ...